MCOLN2 and prostate carcinoma: Prostate cancers with high MCOLN2 mRNA expression were more frequently (69.9% of cases) positive for ERG fusions than cancers with low MCOLN2 mRNA expression (26.5% of cases positive, Fisher’s exact test p = 0.0001).